Lisata Therapeutics CEO David Mazzo on Q3 results; updates on key clinical trials and partnerships

Proactive - Interviews for investors

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo takes Proactive's Stephen Gunnion through the latest updates on the company's clinical trials and financial standing. Following the release of third-quarter results, Mazzo highlighted advancements in Lisata's pancreatic cancer program, specifically the ASCEND trial, which is expected to yield important data soon. He noted that the data from this trial’s first cohort would be presented at the upcoming American Society of Clinical Oncology (ASCO) GI Cancers Symposium. Further, Mazzo discussed significant progress in the BOLSTER trial for first-line cholangiocarcinoma and the ILSTA trial targeting advanced pancreatic cancer. In a noteworthy development, Lisata concluded the quarter with a solid cash position of nearly $36 million, extending its operational runway into 2026. Mazzo also announced two new collaborations—one with Valo Therapeutics in Finland, exploring melanoma treatment, and another with the University of Cincinnati, marking Lisata’s first non-oncology project focused on endometriosis. According to Mazzo, 'Endometriosis affects nearly 90 million women globally, and we hope our work with certepetide can lead to effective treatment options.' Lisata’s CEO hinted at additional commercial collaborations, both oncology and non-oncology, expected in the coming months. For a detailed timeline, Mazzo encouraged investors to review Lisata’s corporate presentation on its website, showcasing key milestones anticipated throughout 2025. Visit Proactive’s YouTube channel for more videos like this, and don't forget to like the video, subscribe to our channel, and enable notifications to stay updated on future content." #LisataTherapeutics #DavidMazzo #ClinicalTrials #PancreaticCancer #Cholangiocarcinoma #ASCENDTrial #BOLSTERTrial #OncologyResearch #EndometriosisResearch #InvestingInBiotech #BiotechNews #ProactiveInvestors #Nasdaq #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews